05.08.2020 Carl Zeiss Meditec AG  DE0005313704

DGAP-News: Carl Zeiss Meditec reports decline in revenue due to COVID-19 pandemic


 

DGAP-News: Carl Zeiss Meditec AG / Key word(s): 9 Month figures
Carl Zeiss Meditec reports decline in revenue due to COVID-19 pandemic

05.08.2020 / 07:00
The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec reports decline in revenue due to COVID-19 pandemic
 
Revenue lower by around 6% year-on-year after nine months 2019/20
 

JENA, 5 August 2020

Carl Zeiss Meditec generated revenue of €967.9m in the first nine months of fiscal year 2019/20 (prior year: €1,027.6m), a decline of -5.8% (adjusted for currency effects: -6.9%) compared with the same period of the prior year. Earnings before interest and taxes (EBIT) decreased to €111.9m (prior year: €184.2m). The EBIT margin was 11.6% (prior year: 17.9%).

"The effects of the COVID-19 pandemic impacted us significantly, particularly in the third quarter of fiscal year 2019/20. Although there has already been a slight recovery in some parts of APAC[1], the measures to contain the COVID-19 pandemic in Europe and North America had a marked effect on our customers and thus demand for our products," said Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.

Both strategic business units report declines in revenue

Revenue in the Ophthalmic Devices strategic business unit (SBU) decreased by -7.0% in the first nine months of fiscal year 2019/20 (adjusted for currency effects: -8.0%), to €709.1m (prior year: €762.7m).
Revenue in the Microsurgery SBU decreased by -2.3% (adjusted for currency effects: -3.6%), to €258.7m (prior year: €264.9m).

Stable performance in APAC region - significant declines in EMEA[2] and Americas

Revenue in the EMEA region decreased by -12.8% (adjusted for currency effects: -12.7%), to €268.8m (prior year: €308.2m). Declines were recorded particularly in the markets worst affected by the COVID-19 pandemic in Western Europe, the UK, Turkey and the Middle East region. In Germany, a recovery was well underway towards the end of the reporting period.

The Americas region recorded a revenue decline of -6.9% (adjusted for currency effects: -9.0%), to €272.3m (prior year: €292.5m). In the third quarter, revenue decreased significantly in the USA and Brazil in particular, after both had achieved growth at the start of the fiscal year.

With revenue of €426.8m, the APAC region almost reached the prior year's figure of €426.9m (adjusted for currency effects: -1.1%). That performance was bolstered by a robust recovery in China and South Korea in the third quarter, after in particular temporary closures of clinics and postponements of elective surgery had previously led to significant revenue losses in the months of February and March. The markets of Japan, India and Southeast Asia, on the other hand, showed a clear decline in the third quarter.

Operating result below prior year

The operating result (earnings before interest and taxes: EBIT) decreased in the first nine months of fiscal year 2019/20, to €111.9m (prior year: €184.2m). The EBIT margin declined to 11.6% (prior year: 17.9%). Adjusted for special items, this amounted to 12.1% (prior year: 18.2%). Earnings per share fell to €0.77 (prior year: €1.22).

"As already announced in July, we are projecting revenue of around €1.3bn for fiscal year 2019/20. This is based on the assumption that the markets will continue to recover and that no additional measures to contain the COVID-19 pandemic will be necessary," added Dr. Ludwin Monz. "Our entire focus remains on protecting our employees, continuity of supply for our customers, and continuing with our strategic investments, so that we can return to sustainable growth as soon as possible."

 

Revenue by strategic business unit

All figures in €m 9 months 2019/20 9 months 2018/19 Change from prior year Change from prior year (adjusted for currency effects)
Ophthalmic Devices 709.1 762.7 -7.0% -8.0%
Microsurgery 258.7 264.9 -2.3% -3.6%
Overall group 967.9 1,027.6 -5.8% -6.9%
 

 

Revenue by region

All figures in €m 9 months 2019/20 9 months 2018/19 Change from prior year Change from prior year (adjusted for currency effects)
EMEA 268.8 308.2 -12.8% -12.7%
Americas 272.3 292.5 -6.9% -9.0%
APAC 426.8 426.9 0.0% -1.1%
Overall group 967.9 1,027.6 -5.8% -6.9%
 

 

Contact for investors and press

Sebastian Frericks
Director Investor Relations, Carl Zeiss Meditec AG
Phone: +49 (0)3641 220-116
E-mail: [email protected]

www.zeiss.com/press

[1] Asia/Pacific
[2] Europe, Middle East, Africa



05.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: [email protected]
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1110179

 
End of News DGAP News Service

1110179  05.08.2020 

fncls.ssp?fn=show_t_gif&application_id=1110179&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 1.088,37 1.189,90 1.280,86 1.459,32 1.335,45 1.646,79 1.710,00
EBITDA1,2 174,56 205,07 228,41 313,03 237,98 435,20 407,50
EBITDA-Marge3 16,04 17,23 17,83 21,45 17,82 26,43 23,83
EBIT1,4 154,33 180,83 197,13 264,66 177,55 373,61 344,00
EBIT-Marge5 14,18 15,20 15,39 18,14 13,30 22,69 20,12
Jahresüberschuss1 99,97 135,78 126,23 160,58 123,42 237,52 221,00
Netto-Marge6 9,19 11,41 9,86 11,00 9,24 14,42 12,92
Cashflow1,7 111,77 37,73 187,21 219,63 178,53 362,66 0,00
Ergebnis je Aktie8 1,21 1,57 1,41 1,79 1,37 2,64 2,42
Dividende8 0,42 0,55 0,55 0,65 0,50 0,90 0,90
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ernst & Young

XETR:AFX Charts by TradingView (c)


INVESTOR-INFORMATIONEN
©boersengefluester.de
Carl Zeiss Meditec
WKN Kurs in € Einschätzung Börsenwert in Mio. €
531370 147,400 Halten 13.183,54
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
46,79 31,92 1,47 96,66
KBV KCV KUV EV/EBITDA
8,35 36,35 8,01 28,13
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,50 0,90 0,61 30.03.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
11.02.2022 13.05.2022 05.08.2022 10.12.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-16,14% -13,09% -20,26% 25,02%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Carl Zeiss Meditec AG  ISIN: DE0005313704 können Sie bei DGAP abrufen


Medtech , 531370 , AFX , XETR:AFX